{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:24:39Z","timestamp":1783398279178,"version":"3.54.6"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Many people living with chronic kidney disease (CKD) are iron deficient, even though they may not be anaemic. The Iron and Muscle study aims to evaluate whether iron supplementation reduces symptoms of fatigue, improves muscle metabolism, and leads to enhanced exercise capacity and physical function. We report here the trial design and baseline characteristics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a prospective, double-blind multicentre randomised controlled trial (RCT) including 75 non-dialysis stage 3\u20134 CKD patients with iron deficiency but without anaemia. Patients were randomly (1:1) assigned to either: i) intravenous iron therapy, or ii) placebo, with concurrent recruitment of eight CKD non-iron deficient participants and six healthy volunteers. The primary outcome of the study is the six-minute walk test (6MWT) distance between baseline and four-weeks. An additional exercise training programme for patients in both groups was initiated and completed between 4 and 12\u00a0weeks, to determine the effect of iron repletion compared to placebo treatment in the context of patients undertaking an exercise programme. Additional secondary outcomes include fatigue, physical function, muscle strength, muscle metabolism, quality of life, resting blood pressure, clinical chemistry, safety and harms associated with the iron therapy intervention and the exercise training intervention, and hospitalisations. All outcomes were conducted at baseline, 4, and 12\u00a0weeks, with a nested qualitative study, to investigate the experience of living with iron deficiency and intervention acceptability. The cohort have been recruited and baseline assessments undertaken.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Seventy-five individuals were recruited. 44% of the randomised cohort were male, the mean (SD) age was 58 (14) years, and 56% were White. Body mass index was 31 (7) kg\/m<jats:sup>2<\/jats:sup>; serum ferritin was 59 (45) \u03bcg\/L, transferrin saturation was 22 (10) %, and haemoglobin was 125 (12) g\/L at randomisation for the whole group. Estimated glomerular filtration rate was 35 (12) mL\/min\/1.73 m<jats:sup>2<\/jats:sup> and the baseline 6MWT distance was 429 (174) m.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The results from this study will address a substantial knowledge gap in the effects of intravenous iron therapy, and offer potential clinical treatment options, to improve exercise capacity, physical function, fatigue, and muscle metabolism, for non-dialysis patients with CKD who are iron-deficient but not anaemic. It will also offer insight into the potential novel effects of an 8-week exercise training programme.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>EudraCT: 2018\u2013000,144-25 Registered 28\/01\/2019.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-022-02896-3","type":"journal-article","created":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T17:16:03Z","timestamp":1658942163000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The effect of intravenous iron supplementation on exercise capacity in iron-deficient but not anaemic patients with chronic kidney disease: study design and baseline data for a multicentre prospective double-blind randomised controlled trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Sharlene A.","family":"Greenwood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Beckley-Hoelscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Asgari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Ayis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke A.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasish","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Bramham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Chilcot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A.","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney J.","family":"Lightfoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"McCafferty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"Mercer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darlington O.","family":"Okonko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chante","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline A.","family":"Swift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Mangelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain C.","family":"Macdougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,27]]},"reference":[{"key":"2896_CR1","unstructured":"Organisation WH. WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations 2021"},{"issue":"5","key":"2896_CR2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1034\/j.1600-0609.2000.065005285.x","volume":"65","author":"VF Fairbanks","year":"2000","unstructured":"Fairbanks VF, Tefferi A. Normal ranges for packed cell volume and hemoglobin concentration in adults: relevance to \u201capparent polycythemia.\u201d Eur J Haematol. 2000;65(5):285\u201396.","journal-title":"Eur J Haematol"},{"issue":"1","key":"2896_CR3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/MAJ.0b013e318095a4ae","volume":"334","author":"A Dunn","year":"2007","unstructured":"Dunn A, Lo V, Donnelly S. The role of the kidney in blood volume regulation: the kidney as a regulator of the hematocrit. Am J Med Sci. 2007;334(1):65\u201371.","journal-title":"Am J Med Sci"},{"issue":"7","key":"2896_CR4","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/ejhf.467","volume":"18","author":"M Stugiewicz","year":"2016","unstructured":"Stugiewicz M, Tkaczyszyn M, Kasztura M, Banasiak W, Ponikowski P, Jankowska EA. The influence of iron deficiency on the functioning of skeletal muscles: experimental evidence and clinical implications. Eur J Heart Fail. 2016;18(7):762\u201373.","journal-title":"Eur J Heart Fail"},{"issue":"29","key":"2896_CR5","doi-asserted-by":"crossref","first-page":"13827","DOI":"10.1016\/S0021-9258(18)67094-2","volume":"261","author":"LJ Cartier","year":"1986","unstructured":"Cartier LJ, Ohira Y, Chen M, Cuddihee RW, Holloszy JO. Perturbation of mitochondrial composition in muscle by iron deficiency. Implications regarding regulation of mitochondrial assembly. J Biol Chem. 1986;261(29):13827\u201332.","journal-title":"J Biol Chem"},{"key":"2896_CR6","first-page":"116","volume":"89","author":"CA Finch","year":"1976","unstructured":"Finch CA, Mackler B. Striate muscle dysfunction in iron deficiency. Trans Assoc Am Physicians. 1976;89:116\u201321.","journal-title":"Trans Assoc Am Physicians"},{"issue":"9","key":"2896_CR7","doi-asserted-by":"crossref","first-page":"442","DOI":"10.52586\/4958","volume":"26","author":"S Bhandari","year":"2021","unstructured":"Bhandari S. Impact of intravenous iron on cardiac and skeletal oxidative stress and cardiac mitochondrial function in experimental uraemia chronic kidney disease. Frontiers in Bioscience-Landmark. 2021;26(9):442\u201364.","journal-title":"Frontiers in Bioscience-Landmark"},{"key":"2896_CR8","doi-asserted-by":"publisher","unstructured":"Nuhu F, Seymour A-M, Bhandari S. Impact of Intravenous Iron on Oxidative Stress and Mitochondrial Function in Experimental Chronic Kidney Disease. Antioxidants. 2019;8(10):498. https:\/\/doi.org\/10.3390\/antiox8100498.","DOI":"10.3390\/antiox8100498"},{"issue":"2","key":"2896_CR9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jacc.2007.09.036","volume":"51","author":"DO Okonko","year":"2008","unstructured":"Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol. 2008;51(2):103\u201312.","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"2896_CR10","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","volume":"361","author":"SD Anker","year":"2009","unstructured":"Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436\u201348.","journal-title":"N Engl J Med"},{"issue":"31","key":"2896_CR11","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1093\/eurheartj\/ehab234","volume":"42","author":"EA Jankowska","year":"2011","unstructured":"Jankowska EA, Kirwan B-A, Kosiborod M, Butler J, Anker SD, McDonagh T, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. Eur Heart J. 2011;42(31):3011\u201320.","journal-title":"Eur Heart J"},{"issue":"11","key":"2896_CR12","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","volume":"36","author":"P Ponikowski","year":"2014","unstructured":"Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency\u2020. Eur Heart J. 2014;36(11):657\u201368.","journal-title":"Eur Heart J"},{"issue":"1","key":"2896_CR13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12882-021-02308-y","volume":"22","author":"S Bhandari","year":"2021","unstructured":"Bhandari S, Allgar V, Lamplugh A, Macdougall I, Kalra PA. A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric Derisomaltose (FDI)) in Iron deficient but not anaemic patients with chronic kidney disease on functional status. BMC Nephrol. 2021;22(1):115.","journal-title":"BMC Nephrol"},{"issue":"11","key":"2896_CR14","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1016\/j.ekir.2021.07.032","volume":"6","author":"JB Wish","year":"2021","unstructured":"Wish JB, Anker SD, Butler J, Cases A, Stack AG, Macdougall IC. Iron Deficiency in CKD Without Concomitant Anemia. Kidney International Reports. 2021;6(11):2752\u201362.","journal-title":"Kidney International Reports"},{"issue":"6762","key":"2896_CR15","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1136\/bmj.301.6762.1199","volume":"301","author":"A David","year":"1990","unstructured":"David A, Pelosi A, McDonald E, Stephens D, Ledger D, Rathbone R, et al. Tired, weak, or in need of rest: fatigue among general practice attenders. BMJ. 1990;301(6762):1199\u2013202.","journal-title":"BMJ"},{"issue":"3","key":"2896_CR16","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/ki.2014.86","volume":"86","author":"M Artom","year":"2014","unstructured":"Artom M, Moss-Morris R, Caskey F, Chilcot J. Fatigue in advanced kidney disease. Kidney Int. 2014;86(3):497\u2013505.","journal-title":"Kidney Int"},{"issue":"7","key":"2896_CR17","first-page":"532","volume":"6","author":"PG Yazdi","year":"2013","unstructured":"Yazdi PG, Moradi H, Yang JY, Wang PH, Vaziri ND. Skeletal muscle mitochondrial depletion and dysfunction in chronic kidney disease. Int J Clin Exp Med. 2013;6(7):532\u20139.","journal-title":"Int J Clin Exp Med"},{"issue":"6","key":"2896_CR18","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1038\/ki.2013.473","volume":"85","author":"M Tamaki","year":"2014","unstructured":"Tamaki M, Miyashita K, Wakino S, Mitsuishi M, Hayashi K, Itoh H. Chronic kidney disease reduces muscle mitochondria and exercise endurance and its exacerbation by dietary protein through inactivation of pyruvate dehydrogenase. Kidney Int. 2014;85(6):1330\u20139.","journal-title":"Kidney Int"},{"key":"2896_CR19","doi-asserted-by":"publisher","unstructured":"Gamboa JL, Billings FT, Bojanowski MT, Gilliam LA, Yu C, Roshanravan B, Roberts LJ, Himmelfarb J, Ikizler TA, Brown NJ. Mitochondrial dysfunction and oxidative stress in patients with chronic kidney disease. Physiol Rep. 2016;4(9):e12780. https:\/\/doi.org\/10.14814\/phy2.12780.","DOI":"10.14814\/phy2.12780"},{"issue":"2","key":"2896_CR20","doi-asserted-by":"crossref","first-page":"F161","DOI":"10.1152\/ajprenal.00437.2020","volume":"320","author":"DL Kirkman","year":"2021","unstructured":"Kirkman DL, Bohmke N, Carbone S, Garten RS, Rodriguez-Miguelez P, Franco RL, et al. Exercise intolerance in kidney diseases: physiological contributors and therapeutic strategies. American Journal of Physiology-Renal Physiology. 2021;320(2):F161\u201373.","journal-title":"American Journal of Physiology-Renal Physiology"},{"issue":"6","key":"2896_CR21","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/abm\/kay061","volume":"53","author":"F Picariello","year":"2019","unstructured":"Picariello F, Norton S, Moss-Morris R, Macdougall IC, Chilcot J. Fatigue in Prevalent Haemodialysis Patients Predicts All-cause Mortality and Kidney Transplantation. Ann Behav Med. 2019;53(6):501\u201314.","journal-title":"Ann Behav Med"},{"key":"2896_CR22","doi-asserted-by":"crossref","unstructured":"ATS statement: guidelines for the six-minute walk test. American journal of respiratory and critical care medicine. 2002;166(1):111\u20137.","DOI":"10.1164\/ajrccm.166.1.at1102"},{"issue":"8","key":"2896_CR23","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2522\/ptj.20100141","volume":"91","author":"E Segura-Orti","year":"2011","unstructured":"Segura-Orti E, Martinez-Olmos FJ. Test-retest reliability and minimal detectable change scores for sit-to-stand-to-sit tests, the six-minute walk test, the one-leg heel-rise test, and handgrip strength in people undergoing hemodialysis. Phys Ther. 2011;91(8):1244\u201352.","journal-title":"Phys Ther"},{"key":"2896_CR24","unstructured":"Hays. KDQOL-SF User\u2019s Manual. Santa Monica, CA USA: RAND; 1997."},{"issue":"3","key":"2896_CR25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/01823246-201223030-00002","volume":"23","author":"MJ Shoemaker","year":"2012","unstructured":"Shoemaker MJ, Curtis AB, Vangsnes E, Dickinson MG. Triangulating Clinically Meaningful Change in the Six-minute Walk Test in Individuals with Chronic Heart Failure: A Systematic Review. Cardiopulm Phys Ther J. 2012;23(3):5\u201315.","journal-title":"Cardiopulm Phys Ther J"},{"issue":"3","key":"2896_CR26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01823246-201324030-00004","volume":"24","author":"MJ Shoemaker","year":"2013","unstructured":"Shoemaker MJ, Curtis AB, Vangsnes E, Dickinson MG. Clinically meaningful change estimates for the six-minute walk test and daily activity in individuals with chronic heart failure. Cardiopulm Phys Ther J. 2013;24(3):21\u20139.","journal-title":"Cardiopulm Phys Ther J"},{"issue":"25","key":"2896_CR27","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","volume":"361","author":"SD Anker","year":"2009","unstructured":"Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. N Engl J Med. 2009;361(25):2436\u201348.","journal-title":"N Engl J Med"},{"issue":"2","key":"2896_CR28","doi-asserted-by":"crossref","first-page":"e12519","DOI":"10.1111\/ijn.12519","volume":"23","author":"Q Tang","year":"2017","unstructured":"Tang Q, Yang B, Fan F, Li P, Yang L, Guo Y. Effects of individualized exercise program on physical function, psychological dimensions, and health-related quality of life in patients with chronic kidney disease: A randomized controlled trial in China. Int J Nurs Pract. 2017;23(2):e12519.","journal-title":"Int J Nurs Pract"},{"issue":"8","key":"2896_CR29","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1007\/s00421-013-2628-5","volume":"113","author":"EL Watson","year":"2013","unstructured":"Watson EL, Kosmadakis GC, Smith AC, Viana JL, Brown JR, Molyneux K, et al. Combined walking exercise and alkali therapy in patients with CKD4-5 regulates intramuscular free amino acid pools and ubiquitin E3 ligase expression. Eur J Appl Physiol. 2013;113(8):2111\u201324.","journal-title":"Eur J Appl Physiol"},{"key":"2896_CR30","doi-asserted-by":"crossref","unstructured":"Watson EL, Viana JL, Wimbury D, Martin N, Greening NJ, Barratt J, et al. The Effect of Resistance Exercise on Inflammatory and Myogenic Markers in Patients with Chronic Kidney Disease. Frontiers in Physiology. 2017;8.","DOI":"10.3389\/fphys.2017.00541"},{"key":"2896_CR31","unstructured":"Guideline on adjustment for baseline covariates in clinical trials EMA\/CHMP\/295050\/2013."},{"key":"2896_CR32","doi-asserted-by":"crossref","unstructured":"Committee for Proprietary Medicinal Products (CPMP): points to consider on adjustment for baseline covariates. Statistics in medicine. 2004;23(5):701\u20139.","DOI":"10.1002\/sim.1647"},{"issue":"1","key":"2896_CR33","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2288-14-20","volume":"14","author":"BC Kahan","year":"2014","unstructured":"Kahan BC. Accounting for centre-effects in multicentre trials with a binary outcome \u2013 when, why, and how? BMC Med Res Methodol. 2014;14(1):20.","journal-title":"BMC Med Res Methodol"},{"issue":"9","key":"2896_CR34","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1177\/0962280216683570","volume":"27","author":"TR Sullivan","year":"2018","unstructured":"Sullivan TR, White IR, Salter AB, Ryan P, Lee KJ. Should multiple imputation be the method of choice for handling missing data in randomized trials? Stat Methods Med Res. 2018;27(9):2610\u201326.","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"2896_CR35","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12874-017-0442-1","volume":"17","author":"JC Jakobsen","year":"2017","unstructured":"Jakobsen JC, Gluud C, Wetterslev J, Winkel P. When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts. BMC Med Res Methodol. 2017;17(1):162.","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"2896_CR36","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/19466315.2020.1779122","volume":"12","author":"RD Meyer","year":"2020","unstructured":"Meyer RD, Ratitch B, Wolbers M, Marchenko O, Quan H, Li D, et al. Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic. Stat Biopharm Res. 2020;12(4):399\u2013411.","journal-title":"Stat Biopharm Res"},{"issue":"6","key":"2896_CR37","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1159\/000507872","volume":"51","author":"S Bhandari","year":"2020","unstructured":"Bhandari S, Allgar V, Lamplugh A, Macdougall IC, Kalra PA. Protocol and Baseline Data of a Multicentre Prospective Double-Blinded Randomized Study of Intravenous Iron on Functional Status in Patients with Chronic Kidney Disease. Am J Nephrol. 2020;51(6):493\u2013500.","journal-title":"Am J Nephrol"},{"issue":"5","key":"2896_CR38","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1365-2524.2004.00507.x","volume":"12","author":"M Hussain-Gambles","year":"2004","unstructured":"Hussain-Gambles M, Atkin K, Leese B. Why ethnic minority groups are under-represented in clinical trials: a review of the literature. Health Soc Care Community. 2004;12(5):382\u20138.","journal-title":"Health Soc Care Community"},{"issue":"4","key":"2896_CR39","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/ACM.0000000000002027","volume":"93","author":"SE Geller","year":"2018","unstructured":"Geller SE, Koch AR, Roesch P, Filut A, Hallgren E, Carnes M. The More Things Change, the More They Stay the Same: A Study to Evaluate Compliance With Inclusion and Assessment of Women and Minorities in Randomized Controlled Trials. Acad Med. 2018;93(4):630\u20135.","journal-title":"Acad Med"},{"issue":"2","key":"2896_CR40","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.2105\/AJPH.2013.301706","volume":"104","author":"S George","year":"2014","unstructured":"George S, Duran N, Norris K. A systematic review of barriers and facilitators to minority research participation among African Americans, Latinos, Asian Americans, and Pacific Islanders. Am J Public Health. 2014;104(2):e16-31.","journal-title":"Am J Public Health"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02896-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-022-02896-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02896-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T11:29:09Z","timestamp":1659094149000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-022-02896-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,27]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2896"],"URL":"https:\/\/doi.org\/10.1186\/s12882-022-02896-3","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,27]]},"assertion":[{"value":"22 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol and related documents were approved by Brent Research Ethics Committee, UK (REC) 19\/LO\/0128, the Health Research Authority and the UK Medicines and Healthcare products Regulatory Agency (MHRA). The study was prospectively registered on 28\/01\/2019 (EudraCT 2018\u2013000144-25). All methods were carried out in accordance with relevant guidelines and regulations. Informed consent was obtained from all subjects and\/or their legal guardian(s).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SB is a Trustee of Kidney Research UK. Other authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"268"}}